Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14927204 | 1.00 | GPR119 (0.54) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL14912467 | 0.87 | SMARCA2 (0.54) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL30176849 | 0.87 | SMARCA2 (0.54) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL31247616 | 0.87 | GPR119 (0.52) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL14924376 | 0.87 | SMARCA2 (0.54) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL30512308 | 0.87 | SMARCA2 (0.54) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL14912289 | 0.87 | SMARCA2 (0.54) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL15935006 | 0.85 | GPR119 (0.50) | GPR119LMNATP53THRBSMARCA2 | |
| SCHEMBL14927206 | 0.85 | MEN1 (0.45) | GPR119MAPTMEN1TSHRKMT2A | |
| SCHEMBL24649825 | 0.84 | GPR119 (0.52) | GPR119LMNATP53THRBSMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250103-A1 | PROCESS FOR PREPARING BTK INHIBITORS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11661424-B2 | Process for preparing BTK inhibitors | GENENTECH, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250103-A1 | PROCESS FOR PREPARING BTK INHIBITORS | BTK, SYK, LYN | GPR119 4259/4885LMNA 3033/4885TP53 3661/4885 |
| US-11661424-B2 | Process for preparing BTK inhibitors | BTK, SYK, LYN | GPR119 4259/4885LMNA 3033/4885TP53 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.